PFI-90 has been developed as a selective inhibitor of KDM3B (patent no. WO2021101929), but it still needs to be further validated whether its inhibitory activity is specific for KDM3B and be tested for its anti-tumor activity. The gene discussed is KDM3B; the disease is neoplasm.